{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:47:47Z","timestamp":1791488867081,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["FDN 148439"],"award-info":[{"award-number":["FDN 148439"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Tesari Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite potent anti-malarial treatment, mortality rates associated with severe falciparum malaria remain high. To attempt to improve outcome, several trials have assessed a variety of potential adjunctive therapeutics, however none to date has been shown to be beneficial. This may be due, at least partly, to the therapeutics chosen and clinical trial design used. Here, we highlight three themes that could facilitate the choice and evaluation of putative adjuvant interventions for severe malaria, paving the way for their assessment in randomized controlled trials. Most clinical trials of adjunctive therapeutics to date have been underpowered due to the large number of participants required to reach mortality endpoints, rendering these study designs challenging and expensive to conduct. These limitations may be mitigated by the use of risk-stratification of participants and application of surrogate endpoints. Appropriate surrogate endpoints include direct measures of pathways causally involved in the pathobiology of severe and fatal malaria, including markers of host immune and endothelial activation and microcirculatory dysfunction. We propose using circulating markers of these pathways to identify high-risk participants that would be most likely to benefit from adjunctive therapy, and further by adopting these biomarkers as surrogate endpoints; moreover, choosing interventions that target deleterious host immune responses that directly contribute to microcirculatory dysfunction, multi-organ dysfunction and death; and, finally, prioritizing where possible, drugs that act on these pathways that are already approved by the FDA, or other regulators, for other indications, and are known to be safe in target populations, including children. An emerging understanding of the critical role of the host response in severe malaria pathogenesis may facilitate both clinical trial design and the search of effective adjunctive therapeutics.<\/jats:p>","DOI":"10.1186\/s12936-020-03340-3","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T13:03:32Z","timestamp":1595595812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical trials to assess adjuvant therapeutics for severe malaria"],"prefix":"10.1186","volume":"19","author":[{"given":"Rosauro","family":"Varo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Erice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quique","family":"Bassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-1272","authenticated-orcid":false,"given":"Kevin C.","family":"Kain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"3340_CR1","volume-title":"World malaria report","author":"WHO","year":"2019","unstructured":"WHO. World malaria report. Geneva: World Health Organization; 2019."},{"key":"3340_CR2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4269\/ajtmh.14-0841","volume":"93","author":"SC Wassmer","year":"2015","unstructured":"Wassmer SC, Taylor TE, Rathod PK, Mishra SK, Mohanty S, Arevalo-Herrera M, et al. Investigating the pathogenesis of severe malaria: a multidisciplinary and cross-geographical approach. Am J Trop Med Hyg. 2015;93:42\u201356.","journal-title":"Am J Trop Med Hyg"},{"key":"3340_CR3","doi-asserted-by":"crossref","first-page":"e20161965","DOI":"10.1542\/peds.2016-1965","volume":"138","author":"JM Ssenkusu","year":"2016","unstructured":"Ssenkusu JM, Hodges JS, Opoka RO, Idro R, Shapiro E, John CC, et al. Long-term behavioral problems in children with severe malaria. Pediatrics. 2016;138:e20161965.","journal-title":"Pediatrics"},{"key":"3340_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lindif.2015.01.010","volume":"46","author":"P Bangirana","year":"2016","unstructured":"Bangirana P, Opoka RO, Boivin MJ, Idro R, Hodges JS, John CC. Neurocognitive domains affected by cerebral malaria and severe malarial anemia in children. Learn Individ Differ. 2016;46:38\u201344.","journal-title":"Learn Individ Differ."},{"key":"3340_CR5","doi-asserted-by":"crossref","first-page":"e20181026","DOI":"10.1542\/peds.2018-1026","volume":"143","author":"JT Langfitt","year":"2019","unstructured":"Langfitt JT, McDermott MP, Brim R, Mboma S, Potchen MJ, Kampondeni SD, et al. Neurodevelopmental impairments 1\u00a0year after cerebral malaria. Pediatrics. 2019;143:e20181026.","journal-title":"Pediatrics"},{"key":"3340_CR6","volume-title":"Global technical strategy for malaria 2016\u20132030","author":"WHO","year":"2015","unstructured":"WHO. Global technical strategy for malaria 2016\u20132030. Geneva: World Health Organization; 2015."},{"key":"3340_CR7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/415673a","volume":"415","author":"LH Miller","year":"2002","unstructured":"Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002;415:673\u20139.","journal-title":"Nature"},{"key":"3340_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.pt.2018.07.011","volume":"34","author":"EKK Glennon","year":"2018","unstructured":"Glennon EKK, Dankwa S, Smith JD, Kaushansky A. Opportunities for host-targeted therapies for malaria. Trends Parasitol. 2018;34:843\u201360.","journal-title":"Trends Parasitol."},{"key":"3340_CR9","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/21505594.2019.1696621","volume":"10","author":"C Erice","year":"2019","unstructured":"Erice C, Kain KC. New insights into microvascular injury to inform enhanced diagnostics and therapeutics for severe malaria. Virulence. 2019;10:1034\u201346.","journal-title":"Virulence."},{"key":"3340_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12936-018-2195-7","volume":"17","author":"R Varo","year":"2018","unstructured":"Varo R, Crowley VM, Sitoe A, Madrid L, Serghides L, Kain KC, et al. Adjunctive therapy for severe malaria: a review and critical appraisal. Malar J. 2018;17:47.","journal-title":"Malar J."},{"key":"3340_CR11","doi-asserted-by":"crossref","first-page":"e0169307","DOI":"10.1371\/journal.pone.0169307","volume":"12","author":"A Jeeyapant","year":"2017","unstructured":"Jeeyapant A, Kingston HW, Plewes K, Maude RJ, Hanson J, Herdman MT, et al. Defining surrogate endpoints for clinical trials in severe falciparum malaria. PLoS ONE. 2017;12:e0169307.","journal-title":"PLoS ONE"},{"key":"3340_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.11604\/pamj.2017.27.33.11081","volume":"27","author":"B Makumbe","year":"2017","unstructured":"Makumbe B, Tshuma C, Shambira G, Mungati M, Gombe NT, Bangure D, et al. Evaluation of severe malaria case management in Mazowe District, Zimbabwe, 2014. Pan Afr Med J. 2017;27:33.","journal-title":"Pan Afr Med J."},{"key":"3340_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12936-018-2364-8","volume":"17","author":"D Zurovac","year":"2018","unstructured":"Zurovac D, Machini B, Kiptui R, Memusi D, Amboko B, Kigen S, et al. Monitoring health systems readiness and inpatient malaria case-management at Kenyan county hospitals. Malar J. 2018;17:213.","journal-title":"Malar J."},{"issue":"Suppl 1","key":"3340_CR14","first-page":"7","volume":"19","author":"WHO","year":"2014","unstructured":"WHO. Severe malaria. Trop Med Int Health. 2014;19(Suppl 1):7\u2013131.","journal-title":"Trop Med Int Health"},{"key":"3340_CR15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12916-017-0906-5","volume":"15","author":"P Sypniewska","year":"2017","unstructured":"Sypniewska P, Duda JF, Locatelli I, Althaus CR, Althaus F, Genton B. Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis. BMC Med. 2017;15:147.","journal-title":"BMC Med."},{"key":"3340_CR16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm986","volume":"10","author":"TE Taylor","year":"2004","unstructured":"Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosiko NG, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med. 2004;10:143\u20135.","journal-title":"Nat Med"},{"key":"3340_CR17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2875-8-4","volume":"8","author":"EA Okiro","year":"2009","unstructured":"Okiro EA, Al-Taiar A, Reyburn H, Idro R, Berkley JA, Snow RW. Age patterns of severe paediatric malaria and their relationship to Plasmodium falciparum transmission intensity. Malar J. 2009;8:4.","journal-title":"Malar J."},{"key":"3340_CR18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1475-2875-9-282","volume":"9","author":"A Roca-Feltrer","year":"2010","unstructured":"Roca-Feltrer A, Carneiro I, Smith L, Schellenberg JRMA, Greenwood B, Schellenberg D. The age patterns of severe malaria syndromes in sub-Saharan Africa across a range of transmission intensities and seasonality settings. Malar J. 2010;9:282.","journal-title":"Malar J."},{"key":"3340_CR19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s13054-015-1023-5","volume":"19","author":"MT Herdman","year":"2015","unstructured":"Herdman MT, Sriboonvorakul N, Leopold SJ, Douthwaite S, Mohanty S, Hassan MMU, Maude RJ, et al. The role of previously unmeasured organic acids in the pathogenesis of severe malaria. Crit Care. 2015;19:317.","journal-title":"Crit Care"},{"key":"3340_CR20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4103\/0972-9062.263727","volume":"56","author":"N Bhardwaj","year":"2019","unstructured":"Bhardwaj N, Ahmed M, Sharma S, Nayak A, Anvikar A, Pande V. C-reactive protein as a prognostic marker of Plasmodium falciparum malaria severity. J Vector Borne Dis. 2019;56:122\u20136.","journal-title":"J Vector Borne Dis."},{"key":"3340_CR21","first-page":"72","volume":"40","author":"N Carannante","year":"2017","unstructured":"Carannante N, Rossi M, Fraganza F, Coppola G, Chiesa D, Attanasio V, et al. A high PCT level correlates with disease severity in Plasmodium falciparum malaria in children. New Microbiol. 2017;40:72\u20134.","journal-title":"New Microbiol"},{"key":"3340_CR22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/infdis\/jis371","volume":"206","author":"KB Seydel","year":"2012","unstructured":"Seydel KB, Fox LL, Glover SJ, Reeves MJ, Pensulo P, Muiruri A, et al. Plasma concentrations of parasite histidine-rich protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral malaria in Malawian children. J Infect Dis. 2012;206:309\u201318.","journal-title":"J Infect Dis"},{"key":"3340_CR23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/infdis\/jis675","volume":"207","author":"IC Hendriksen","year":"2013","unstructured":"Hendriksen IC, White LJ, Veenemans J, Mtove G, Woodrow C, Amos B, et al. Defining falciparum-malaria-attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentration. J Infect Dis. 2013;207:351\u201361.","journal-title":"J Infect Dis"},{"key":"3340_CR24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0035-9203(94)90504-5","volume":"88","author":"S Krishna","year":"1994","unstructured":"Krishna S, Waller DW, ter Kuile F, Kwiatkowski D, Crawley J, Craddock CF, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg. 1994;88:67\u201373.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3340_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12936-018-2488-x","volume":"17","author":"CR McDonald","year":"2018","unstructured":"McDonald CR, Weckman A, Richard-Greenblatt M, Leligdowicz A, Kain KC. Integrated fever management: disease severity markers to triage children with malaria and non-malarial febrile illness. Malar J. 2018;17:353.","journal-title":"Malar J."},{"key":"3340_CR26","doi-asserted-by":"crossref","first-page":"ofw134","DOI":"10.1093\/ofid\/ofw134","volume":"3","author":"AL Conroy","year":"2016","unstructured":"Conroy AL, Hawkes M, McDonald CR, Kim H, Higgins SJ, Barker KR, et al. Host biomarkers are associated with response to therapy and long-term mortality in pediatric severe malaria. Open Forum Infect Dis. 2016;3:ofw134.","journal-title":"Open Forum Infect Dis."},{"key":"3340_CR27","doi-asserted-by":"crossref","first-page":"e17440","DOI":"10.1371\/journal.pone.0017440","volume":"6","author":"LK Erdman","year":"2011","unstructured":"Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, Higgins S, et al. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS ONE. 2011;6:e17440.","journal-title":"PLoS ONE"},{"key":"3340_CR28","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/tmi.12787","volume":"21","author":"S Adukpo","year":"2016","unstructured":"Adukpo S, Gyan BA, Ofori MF, Dodoo D, Velavan TP, Meyer CG. Triggering receptor expressed on myeloid cells 1 (TREM-1) and cytokine gene variants in complicated and uncomplicated malaria. Trop Med Int Health. 2016;21:1592\u2013601.","journal-title":"Trop Med Int Health."},{"key":"3340_CR29","doi-asserted-by":"crossref","first-page":"e00895","DOI":"10.1128\/IAI.00895-19","volume":"88","author":"J Woodford","year":"2020","unstructured":"Woodford J, Yeo TW, Piera KA, Butler K, Weinberg JB, McCarthy JS, et al. Early endothelial activation precedes glycocalyx degradation and microvascular dysfunction in experimentally induced Plasmodium falciparum and Plasmodium vivax infection. Infect Immun. 2020;88:e00895\u20131019.","journal-title":"Infect Immun"},{"key":"3340_CR30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41426-018-0105-2","volume":"7","author":"BE Barber","year":"2018","unstructured":"Barber BE, Grigg MJ, Piera KA, William T, Cooper DJ, Plewes K, et al. Intravascular haemolysis in severe Plasmodium knowlesi malaria: association with endothelial activation, microvascular dysfunction, and acute kidney injury. Emerg Microbes Infect. 2018;7:106.","journal-title":"Emerg Microbes Infect."},{"key":"3340_CR31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3389\/fimmu.2018.00838","volume":"9","author":"A Leligdowicz","year":"2018","unstructured":"Leligdowicz A, Richard-Greenblatt M, Wright J, Crowley VM, Kain KC. Endothelial activation: the Ang\/Tie axis in sepsis. Front Immunol. 2018;9:838.","journal-title":"Front Immunol."},{"key":"3340_CR32","doi-asserted-by":"crossref","first-page":"358ra128","DOI":"10.1126\/scitranslmed.aaf6812","volume":"8","author":"SJ Higgins","year":"2016","unstructured":"Higgins SJ, Purcell LA, Silver KL, Tran V, Crowley V, Hawkes M, et al. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. Sci Transl Med. 2016;8:358ra128.","journal-title":"Sci Transl Med."},{"key":"3340_CR33","doi-asserted-by":"crossref","first-page":"17097","DOI":"10.1073\/pnas.0805782105","volume":"105","author":"TW Yeo","year":"2008","unstructured":"Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, Price RN, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA. 2008;105:17097\u2013102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3340_CR34","doi-asserted-by":"crossref","first-page":"e4912","DOI":"10.1371\/journal.pone.0004912","volume":"4","author":"FE Lovegrove","year":"2009","unstructured":"Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS ONE. 2009;4:e4912.","journal-title":"PLoS ONE"},{"key":"3340_CR35","doi-asserted-by":"crossref","first-page":"e15291","DOI":"10.1371\/journal.pone.0015291","volume":"5","author":"AL Conroy","year":"2010","unstructured":"Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, Seydel KB, et al. Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study. PLoS ONE. 2010;5:e15291.","journal-title":"PLoS ONE"},{"key":"3340_CR36","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/CCM.0b013e3182373157","volume":"40","author":"AL Conroy","year":"2012","unstructured":"Conroy AL, Glover SJ, Hawkes M, Erdman LK, Seydel KB, Taylor TE, et al. Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study. Crit Care Med. 2012;40:952\u20139.","journal-title":"Crit Care Med"},{"key":"3340_CR37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/1475-2875-8-295","volume":"8","author":"AL Conroy","year":"2009","unstructured":"Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, et al. Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J. 2009;8:295.","journal-title":"Malar J."},{"key":"3340_CR38","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1093\/brain\/awu146","volume":"137","author":"IJ MacCormick","year":"2014","unstructured":"MacCormick IJ, Beare NA, Taylor TE, Barrera V, White VA, Hiscott P, et al. Reply: Retinopathy, histidine-rich protein-2 and perfusion pressure in cerebral malaria. Brain. 2014;137:e299.","journal-title":"Brain"},{"key":"3340_CR39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.trstmh.2005.09.021","volume":"100","author":"T Taylor","year":"2006","unstructured":"Taylor T, Olola C, Valim C, Agbenyega T, Kremsner P, Krishna S, et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg. 2006;100:615\u201322.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3340_CR40","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","volume":"31","author":"TR Fleming","year":"2012","unstructured":"Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31:2973\u201384.","journal-title":"Stat Med"},{"key":"3340_CR41","doi-asserted-by":"crossref","first-page":"e0191550","DOI":"10.1371\/journal.pone.0191550","volume":"13","author":"P Bangirana","year":"2018","unstructured":"Bangirana P, Conroy AL, Opoka RO, Hawkes MT, Hermann L, Miller C, et al. Inhaled nitric oxide and cognition in pediatric severe malaria: a randomized double-blind placebo controlled trial. PLoS ONE. 2018;13:e0191550.","journal-title":"PLoS ONE"},{"key":"3340_CR42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/1475-2875-10-383","volume":"10","author":"V Jain","year":"2011","unstructured":"Jain V, Lucchi NW, Wilson NO, Blackstock AJ, Nagpal AC, Joel PK, et al. Plasma levels of angiopoietin-1 and -2 predict cerebral malaria outcome in Central India. Malar J. 2011;10:383.","journal-title":"Malar J."},{"key":"3340_CR43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/CCM.0b013e318206d285","volume":"39","author":"DR Ricciuto","year":"2011","unstructured":"Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med. 2011;39:702\u201310.","journal-title":"Crit Care Med"},{"key":"3340_CR44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12887-018-1087-x","volume":"18","author":"JK Wright","year":"2018","unstructured":"Wright JK, Hayford K, Tran V, Al Kibria GM, Baqui A, Manajjir A, et al. Biomarkers of endothelial dysfunction predict sepsis mortality in young infants: a matched case-control study. BMC Pediatr. 2018;18:118.","journal-title":"BMC Pediatr."},{"key":"3340_CR45","doi-asserted-by":"crossref","first-page":"e0141251","DOI":"10.1371\/journal.pone.0141251","volume":"10","author":"C Mikacenic","year":"2015","unstructured":"Mikacenic C, Hahn WO, Price BL, Harju-Baker S, Katz R, Kain KC, et al. Biomarkers of Endothelial activation are associated with poor outcome in critical illness. PLoS ONE. 2015;10:e0141251.","journal-title":"PLoS ONE"},{"key":"3340_CR46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12936-015-0946-2","volume":"14","author":"MT Hawkes","year":"2015","unstructured":"Hawkes MT, Conroy AL, Opoka RO, Hermann L, Thorpe KE, McDonald C, et al. Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial. Malar J. 2015;14:421.","journal-title":"Malar J."},{"key":"3340_CR47","doi-asserted-by":"crossref","first-page":"e1003980","DOI":"10.1371\/journal.ppat.1003980","volume":"10","author":"L Serghides","year":"2014","unstructured":"Serghides L, McDonald CR, Lu Z, Friedel M, Cui C, Ho KT, et al. PPARgamma agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. PLoS Pathog. 2014;10:e1003980.","journal-title":"PLoS Pathog"},{"key":"3340_CR48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673\u201383.","journal-title":"Nat Rev Drug Discov."},{"key":"3340_CR49","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2174\/1568026616666160216153618","volume":"16","author":"D Bhattarai","year":"2016","unstructured":"Bhattarai D, Singh S, Jang Y, Hyeon Han S, Lee K, Choi Y. An insight into drug repositioning for the development of novel anti-cancer drugs. Curr Top Med Chem. 2016;16:2156\u201368.","journal-title":"Curr Top Med Chem"},{"key":"3340_CR50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov."},{"key":"3340_CR51","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1810137115","volume":"115","author":"J Janes","year":"2018","unstructured":"Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc Natl Acad Sci USA. 2018;115:10750\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3340_CR52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1574884712666170704144042","volume":"12","author":"HM Brooks","year":"2017","unstructured":"Brooks HM, Hawkes MT. Repurposing pharmaceuticals as neuroprotective agents for cerebral malaria. Curr Clin Pharmacol. 2017;12:62\u201372.","journal-title":"Curr Clin Pharmacol."},{"key":"3340_CR53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12936-017-1858-0","volume":"16","author":"R Varo","year":"2017","unstructured":"Varo R, Crowley VM, Sitoe A, Madrid L, Serghides L, Bila R, et al. Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria. Malar J. 2017;16:215.","journal-title":"Malar J."},{"key":"3340_CR54","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/605431","volume":"49","author":"AK Boggild","year":"2009","unstructured":"Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, et al. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2009;49:841\u20139.","journal-title":"Clin Infect Dis"},{"key":"3340_CR55","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(02)08360-5","volume":"359","author":"L Serghides","year":"2002","unstructured":"Serghides L, Kain KC. Mechanism of protection induced by vitamin A in falciparum malaria. Lancet. 2002;359:1404\u20136.","journal-title":"Lancet"},{"key":"3340_CR56","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.4049\/jimmunol.166.11.6742","volume":"166","author":"L Serghides","year":"2001","unstructured":"Serghides L, Kain KC. Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes\/macrophages. J Immunol. 2001;166:6742\u20138.","journal-title":"J Immunol."},{"key":"3340_CR57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1086\/598222","volume":"199","author":"L Serghides","year":"2009","unstructured":"Serghides L, Patel SN, Ayi K, Lu Z, Gowda DC, Liles WC, et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J Infect Dis. 2009;199:1536\u201345.","journal-title":"J Infect Dis"},{"key":"3340_CR58","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/648409","volume":"200","author":"R Helbok","year":"2009","unstructured":"Helbok R, Kendjo E, Issifou S, Lackner P, Newton CR, Kombila M, et al. The Lambarene Organ Dysfunction Score (LODS) is a simple clinical predictor of fatal malaria in African children. J Infect Dis. 2009;200:1834\u201341.","journal-title":"J Infect Dis"},{"key":"3340_CR59","doi-asserted-by":"crossref","first-page":"e0223457","DOI":"10.1371\/journal.pone.0223457","volume":"14","author":"P Teparrukkul","year":"2019","unstructured":"Teparrukkul P, Hantrakun V, Imwong M, Teerawattanasook N, Wongsuvan G, Day NP, et al. Utility of qSOFA and modified SOFA in severe malaria presenting as sepsis. PLoS ONE. 2019;14:e0223457.","journal-title":"PLoS ONE"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03340-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03340-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03340-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T23:21:11Z","timestamp":1627082471000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03340-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3340"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03340-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"KCK is a named inventor on a patent \u201cBiomarkers for early determination of a critical or life-threatening response to illness and\/or treatment response\u201d held by the University Health Network. Remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}